Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Clearside Biomedical reports positive trial results and strategic leadership changes

Clearside Biomedical's Q3 2024 earnings call highlighted promising trial results, financial stability, and strategic leadership changes.
The company's strengths lie in its innovative suprachoroidal platform, strong partnerships, and positive trial outcomes for wet AMD treatment.
While facing challenges in trial design and funding, Clearside Biomedical has opportunities in geographic atrophy treatment and flexible dosing strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that it has entered into a securities purchase agreement with institutional investors and certain existing stockholders, providing for the purchase and sale of 4,209,050 shares of common stock at a price of $2.851 per share, priced at-the-market under Nasdaq rules based on the five-day average closing price of the common stock, in a registered direct offering, resulting in total gross proceeds of approximately $12.0 million, before deducting the placement agent's fees and other estimated offering expenses.

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Apple

Caterpillar

Disney

Dow Inc

Eiger BioPharmaceuticals

Intel

Johnson & Johnson

JPMorgan Chase & Co

NIKE

Walmart

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg annual returns of +43.8%.

Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW ). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. In this article, we will take a closer look at hedge fund sentiment towards Clearside Biomedical, Inc. (NASDAQ:CLSD).

Here is What Hedge Funds Think About Clearside Biomedical, Inc. (CLSD)

ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology (AAO) 2020 Annual Meeting.

Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology

ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 at 8:40 a.m. ET.

Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference

Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript

- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® Ongoing by  Gene Therapy and Oncology Partners - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third quarter 2020 financial results will be reported on Tuesday, November 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020

Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Clearside Biomedical (CLSD) Enters Oversold Territory

Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure

Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina

ALPHARETTA, Ga., Sept.  11, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, Aura Biosciences, has dosed the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroidal melanoma. Aura is using Clearside’s SCS Microinjector® to deliver AU-011 into the suprachoroidal space (SCS®).

Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery

ALPHARETTA, Ga., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 11:30 a.m. ET.

Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference

ALPHARETTA, Ga., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, REGENXBIO Inc. (Nasdaq: RGNX), has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, an adeno-associated virus (AAV) gene therapy, using Clearside’s SCS Microinjector® for the treatment of wet age-related macular degeneration (wet AMD).

Clearside Biomedical’s Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery

- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE - - New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE -

Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call Transcript

- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -  - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs -  - Engaged New Contract Manufacturer for XIPERE ™  -  - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -

Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update

- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -

Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space

ALPHARETTA, Ga., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 a.m. ET.

Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ALPHARETTA, Ga., July  30, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

ALPHARETTA, Ga., July  27, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) were delivered at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.

Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration –

News for Clearside Biomedical Stock (CLSD)